Home
DSGN
DSGN News

Latest Design Therapeutics Inc. (DSGN) News on November 25, 2025

MT Newswires

5 days ago

Design Therapeutics' Friedreich Ataxia Program Shows Potential, RBC Says

Here Are Thursday’s Top Wall Street Analyst Research Calls: AON, Apollo Global, Bullish, Jack Henry, Marsh & McClennan, Nasdaq, NVIDIA, and More

24/7 Wall St.

5 days ago

Here Are Thursday’s Top Wall Street Analyst Research Calls: AON, Apollo Global, Bullish, Jack Henry, Marsh & McClennan, Nasdaq, NVIDIA, and More

Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results

GlobeNewswire

20 days ago

Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results

Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.

23 days ago

Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans

Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2

GlobeNewswire

6 months ago

Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2

Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference

GlobeNewswire

6 months ago

Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference

3 Penny Stocks With Market Caps As Low As $70M To Watch

Simply Wall St.

6 months ago

3 Penny Stocks With Market Caps As Low As $70M To Watch

Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference

GlobeNewswire

6 months ago

Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference

Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results

GlobeNewswire

7 months ago

Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results

Design Therapeutics reports positive outcomes from trial of DT-168 eye drops

Clinical Trials Arena

7 months ago

Design Therapeutics reports positive outcomes from trial of DT-168 eye drops

MT Newswires

7 months ago

Top Premarket Gainers

MT Newswires

7 months ago

Design Therapeutics Says Eye Drops for Fuchs Endothelial Corneal Dystrophy 'Well-Tolerated'

Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy

GlobeNewswire

7 months ago

Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy

Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025

GlobeNewswire

7 months ago

Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025

April 2025's Promising Penny Stocks

Simply Wall St.

7 months ago

April 2025's Promising Penny Stocks

MT Newswires

7 months ago

Design Therapeutics Names Chris Storgard as Chief Medical Officer

Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer

GlobeNewswire

7 months ago

Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

GlobeNewswire

7 months ago

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

Design Therapeutics (DSGN) Upgraded to Buy: Here's Why

Zacks

8 months ago

Design Therapeutics (DSGN) Upgraded to Buy: Here's Why

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire

9 months ago

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

Design Therapeutics to Participate in Leerink’s Global Healthcare Conference

GlobeNewswire

9 months ago

Design Therapeutics to Participate in Leerink’s Global Healthcare Conference

US Penny Stocks To Watch In February 2025

Simply Wall St.

9 months ago

US Penny Stocks To Watch In February 2025

3 Promising US Penny Stocks With Market Caps Under $900M

Simply Wall St.

10 months ago

3 Promising US Penny Stocks With Market Caps Under $900M

MT Newswires

a year ago

Top Premarket Decliners

Design Therapeutics to Participate in Multiple Upcoming Investor Conferences

GlobeNewswire

a year ago

Design Therapeutics to Participate in Multiple Upcoming Investor Conferences

Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

GlobeNewswire

a year ago

Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely

Simply Wall St.

a year ago

We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely

Pleasing Signs As A Number Of Insiders Buy Design Therapeutics Stock

Simply Wall St.

a year ago

Pleasing Signs As A Number Of Insiders Buy Design Therapeutics Stock

Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

GlobeNewswire

a year ago

Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet

Zacks

a year ago

Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet

With 34% ownership, Design Therapeutics, Inc. (NASDAQ:DSGN) has piqued the interest of institutional investors

Simply Wall St.

a year ago

With 34% ownership, Design Therapeutics, Inc. (NASDAQ:DSGN) has piqued the interest of institutional investors

Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio

GlobeNewswire

a year ago

Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio

GuruFocus.com

2 years ago

Design Therapeutics Inc (DSGN) Q1 2024 Earnings: A Detailed Financial and Strategic Review

Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones

GlobeNewswire

2 years ago

Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones

MT Newswires

2 years ago

--Piper Sandler Upgrades Design Therapeutics to Overweight From Neutral

Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

GlobeNewswire

2 years ago

Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

Independent Director of Design Therapeutics Picks Up 88% More Stock

Simply Wall St.

2 years ago

Independent Director of Design Therapeutics Picks Up 88% More Stock

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Simply Wall St.

2 years ago

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Design Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Design Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Earnings Call Transcript

Thomson Reuters StreetEvents

2 years ago

Q4 2023 Design Therapeutics Inc Earnings Call

GuruFocus.com

2 years ago

Design Therapeutics Inc (DSGN) Reports Full Year 2023 Financial Results and Pipeline Progress

Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire

2 years ago

Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results

Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update

GlobeNewswire

2 years ago

Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update

Organigram Completes First Shipment to Germany, Extending its International Reach

Business Wire

2 years ago

Organigram Completes First Shipment to Germany, Extending its International Reach

Thomson Reuters StreetEvents

2 years ago

Q4 2023 Bridgewater Bancshares Inc Earnings Call

Bridgewater Bancshares Inc (BWB) Reports Q4 Earnings Dip Amidst Market Challenges

GuruFocus.com

2 years ago

Bridgewater Bancshares Inc (BWB) Reports Q4 Earnings Dip Amidst Market Challenges

Online Marketplace Stocks Q3 Teardown: Shutterstock (NYSE:SSTK) Vs The Rest

StockStory

2 years ago

Online Marketplace Stocks Q3 Teardown: Shutterstock (NYSE:SSTK) Vs The Rest

Ares Dynamic Credit Allocation Fund Inc's Dividend Analysis

GuruFocus.com

2 years ago

Ares Dynamic Credit Allocation Fund Inc's Dividend Analysis

Stitch Fix (SFIX) Fortifies With AI Amid Market Challenges

Zacks

2 years ago

Stitch Fix (SFIX) Fortifies With AI Amid Market Challenges

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

GlobeNewswire

2 years ago

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Charles Brandes Adjusts Position in Graham Corp

GuruFocus.com

2 years ago

Charles Brandes Adjusts Position in Graham Corp

The Zacks Analyst Blog Highlights JAKKS Pacific, Hooker Furniture, Netflix, Skillz and Acushnet

Zacks

2 years ago

The Zacks Analyst Blog Highlights JAKKS Pacific, Hooker Furniture, Netflix, Skillz and Acushnet

Reasons to Retain Graco (GGG) Stock in Your Portfolio Now

Zacks

2 years ago

Reasons to Retain Graco (GGG) Stock in Your Portfolio Now

5 Solid Stocks to Buy on a Solid Jump in Factory Orders

Zacks

2 years ago

5 Solid Stocks to Buy on a Solid Jump in Factory Orders

HIVE Digital Provides Recap of Calendar Year 2023 Mining 3,260 Bitcoin

Newsfile

2 years ago

HIVE Digital Provides Recap of Calendar Year 2023 Mining 3,260 Bitcoin

G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

2 years ago

G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Business Wire

2 years ago

CORRECTING and REPLACING Eaton Vance Declares Early Monthly Distributions and Special Distributions for Certain Eaton Vance Closed-End Funds

Perfect Corp (NYSE:PERF): The Vanguard Of Beauty And Fashion Tech Innovation That Helps Brands Drive Sales

ACCESSWIRE

2 years ago

Perfect Corp (NYSE:PERF): The Vanguard Of Beauty And Fashion Tech Innovation That Helps Brands Drive Sales

Design Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should Know

Zacks

2 years ago

Design Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should Know

Sachem Capital Corp. Announces Dividend of $0.11 per Share

GlobeNewswire

2 years ago

Sachem Capital Corp. Announces Dividend of $0.11 per Share

Barings Participation Investors Announces Increased Quarterly Cash Dividend of $0.35 Per Share

Business Wire

2 years ago

Barings Participation Investors Announces Increased Quarterly Cash Dividend of $0.35 Per Share

Strength Seen in First Commonwealth Financial (FCF): Can Its 5.5% Jump Turn into More Strength?

Zacks

2 years ago

Strength Seen in First Commonwealth Financial (FCF): Can Its 5.5% Jump Turn into More Strength?

Despite recent sales, Weyco Group, Inc. (NASDAQ:WEYS) insiders still hold the largest share with a 39% interest

Simply Wall St.

2 years ago

Despite recent sales, Weyco Group, Inc. (NASDAQ:WEYS) insiders still hold the largest share with a 39% interest

Tortoise Provides Unaudited Balance Sheet Information and Asset Coverage Ratio Updates as of November 30, 2023, for TYG, NTG, TTP, NDP and TPZ

ACCESSWIRE

2 years ago

Tortoise Provides Unaudited Balance Sheet Information and Asset Coverage Ratio Updates as of November 30, 2023, for TYG, NTG, TTP, NDP and TPZ

Virtus Convertible & Income Fund II Announces Quarterly Distribution: 5.500% Series A Cumulative Preferred Shares

Business Wire

2 years ago

Virtus Convertible & Income Fund II Announces Quarterly Distribution: 5.500% Series A Cumulative Preferred Shares

Positive Signs As Multiple Insiders Buy Design Therapeutics Stock

Simply Wall St.

2 years ago

Positive Signs As Multiple Insiders Buy Design Therapeutics Stock

Certain Virtus Closed-End Funds Announce Three Monthly Distributions: NCV, NCZ, CBH

Business Wire

2 years ago

Certain Virtus Closed-End Funds Announce Three Monthly Distributions: NCV, NCZ, CBH

GuruFocus.com

2 years ago

Design Therapeutics Inc (DSGN) Reports Q3 2023 Financials, Plans Strategic Update

Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024

GlobeNewswire

2 years ago

Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024

Astria Therapeutics Inc (ATXS) Reports Q3 Financial Results and Corporate Developments

GuruFocus.com

2 years ago

Astria Therapeutics Inc (ATXS) Reports Q3 Financial Results and Corporate Developments

Fulcrum Therapeutics Inc (FULC) Reports Q3 2023 Financial Results and Business Highlights

GuruFocus.com

2 years ago

Fulcrum Therapeutics Inc (FULC) Reports Q3 2023 Financial Results and Business Highlights

Saba Capital Management, L.P. Increases Stake in ASA Gold And Precious Metals Ltd

GuruFocus.com

2 years ago

Saba Capital Management, L.P. Increases Stake in ASA Gold And Precious Metals Ltd

Cerus Corporation to Participate in Upcoming Investor Conferences

Business Wire

2 years ago

Cerus Corporation to Participate in Upcoming Investor Conferences

Share on Social Networks: